DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation

Information source: Allergopharma GmbH & Co. KG
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Allergy; Rhinitis; Conjunctivitis

Intervention: Allerslit forte (Biological); Allerslit forte (Biological)

Phase: Phase 3

Status: Completed

Sponsored by: Allergopharma GmbH & Co. KG

Official(s) and/or principal investigator(s):
Kristian Reich, Professor, Principal Investigator, Affiliation: not affiliated

Summary

Efficacy and Safety from a high-dosed sublingual grass pollen preparation

Clinical Details

Official title: A Multicentre, Multinational, Placebo-controlled, Double-blind, Randomized Study to Evaluate Efficacy and Safety of a Perennial, Sublingual, Specific Immunotherapy in Patients With Rhinoconjunctivitis With/Without Controlled Asthma Caused by Grass Pollen

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Symptom and Medication Score

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Allergic rhinoconjunctivitis attributable to grass pollen

- Positive SPT

- Positive EAST

- Positive provocation Test

Exclusion Criteria:

- Serious chronic disease

- other perennial allergies

Locations and Contacts

Prof. Kristian Reich, MD, Hamburg 20354, Germany
Additional Information

Leader in specific allergy research and therapy

Click here for information about this trial in the European Clinical Trials Register

Starting date: March 2008
Last updated: November 7, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017